Ari Oglesby
Associate Director
HDF Comprehensive Cancer Ctr
School of Medicine

Publications (4)

Top publication keywords:
MelanomaT-Lymphocytes, CytotoxicAntineoplastic Agents, ImmunologicalSkin NeoplasmsTumor MicroenvironmentLymphocytes, Tumor-InfiltratingRadiosurgeryAdministration, IntravenousNeoplasm Recurrence, LocalCancer VaccinesImmunotherapyProgrammed Cell Death 1 ReceptorNeoadjuvant TherapyInjections, IntralesionalT-Lymphocytes, Regulatory

• Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response.
  BJC reports 2024 Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, Levine LS, Sison P, Tsai KK, Chow M, Kang JH, Hwang J, Lee JC, Oglesby A, Venegas J, Brintz BJ, Tan AC, Anderson MS, Rosenblum MD, Young A, …
• Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
  Annals of surgical oncology 2020 Levine LS, Mahuron KM, Tsai KK, Wu C, Mattis DM, Pauli ML, Oglesby A, Lee JC, Spitzer MH, Krummel MF, Algazi AP, Rosenblum MD, Alvarado M, Daud AI
• Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, Francisco M, Fong L, Pittet MJ, Arlauckas SP, Garris C, Levine LP, Bifulco C, Ballesteros-Merino…
• Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers.
  American journal of clinical dermatology 2019 Oglesby A, Algazi AP, Daud AI